Journal article
Gene methylation of CADM1 and MAL identified as a biomarker of high grade anal intraepithelial neoplasia
S Phillips, K Cassells, SM Garland, DA Machalek, JM Roberts, DJ Templeton, F Jin, IM Poynten, RJ Hillman, AE Grulich, GL Murray, SN Tabrizi, M Molano, AM Cornall
Scientific Reports | NATURE PORTFOLIO | Published : 2022
Open access
Abstract
Human papillomavirus (HPV) is detected in up to 96% of anal squamous cell cancers, where screening programs needed. However, the best methodology is still undetermined. Host DNA methylation markers CADM1, MAL and miR124 have been identified in cervical disease, but not anal disease. Anal swabs varying by disease grade were assessed for DNA methylation of CADM1, MAL and miR124-2. Each marker was compared across disease grades, stratified by HPV and HIV status. Receiver operating characteristic curves identified the predictive value of significant gene candidates. CADM1 methylation was significantly higher in high-grade squamous intraepithelial lesions (HSIL) compared with low-grade (LSIL) (p ..
View full abstractGrants
Awarded by Roche
Funding Acknowledgements
This work was supported by National Health and Medical Research Council Program Grant (Sexually Transmitted Infections: causes, consequences, and interventions; grant no. 568971; to A.E. Grulich), Cancer Council New South Wales Strategic Research Partnership Program Grant (Preventing morbidity and mortality from anal cancer; Grant No. 13-11; to A.E. Grulich, I.M. Poynten, F. Jin, RJ Hillman, DJ Templeton, JM Roberts), and Cancer Council Victoria grant for evaluating molecular biomarkers of anal cancer risk (application no. APP1130507; to S.M. Garland, M. Molano, A.M. Cornall). The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales and funded by the Australian Government of Health and Ageing. Cytologic testing materials were provided by Hologic (Australia) Pty Ltd.